Drug Profile
Alpha-galactosidase - Greenovation Biotech
Alternative Names: MOSS-AGAL; Moss-agalsidase; Moss-αGalLatest Information Update: 31 Oct 2021
Price :
$50
*
At a glance
- Originator Greenovation Biotech
- Class Carminatives; Enzymes; Recombinant proteins
- Mechanism of Action Alpha-galactosidase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Fabry's disease
Most Recent Events
- 28 Jun 2019 No recent reports of development identified for phase-I development in Fabry's-disease in Germany (IV, Infusion)
- 09 Oct 2017 Greenovation Biotech completes a phase I trial in Fabry's disease in Germany (IV) (NCT02995993)
- 04 May 2016 Greenovation Biotech files a Clinical Trial Application with the Federal Institute for Drugs and Medical Devices in Germany for Fabry's disease